Bioprofarma Bagó is pleased to present the launch of BIOPONIB® ponatinib for its Hematology Business Unit.

BIOPONIB® ponatinib is approved by ANMAT for the treatment of Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL) in adult patients who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and in whom subsequent treatment with imatinib is not clinically indicated; or who present the T315I mutation.

HOW SUPPLIED:

BIOPONIB® 15 mg x 30 coated tablets
BIOPONIB® 15 mg x 60 coated tablets
BIOPONIB® 45 mg x 60 coated tablets

BIOPONIB® ponatinib joins the portfolio of products for the treatment of CML and ALL PH+, together with CLINID®imatinib and DAPIBUS® dasatinib.

This new treatment alternative comes to provide specialists with more options for the care of their patients.